Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06122779 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Phase 2 study of Heart Failure, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 2
Development phase
208
Enrollment target
20
Study locations

NCT06122779 is a Phase 2 study of Heart Failure that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 208 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06122779, a Phase 2 study of Heart Failure, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 2
Development phase
208 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).

Conditions Studied

Heart Failure

Interventions

  • OTHER Placebo
  • DRUG BMS-986435

Study Locations (20)

New York

  • Capital Cardiology Associates - Albany
  • Local Institution - 0105 - Brooklyn
  • Weill Cornell Medicine - New York
  • University of Rochester Medical Center - PPDS - Rochester
  • Rochester General Hospital Center for Clinical Research - Rochester
  • Laurelton Heart Specialist PC - MyClinical - PPDS - Rosedale

Florida

  • Ascension St. Vincent's Riverside Hospital - PPDS - Jacksonville
  • Local Institution - 0003 - Miami
  • University of Miami FL Miller School of Medicine -1120 NW 14th St - Miami

Georgia

  • Local Institution - 0014 - Atlanta
  • Local Institution - 0048 - Atlanta

Illinois

  • Bluhm Cardiovascular Institute of Northwestern - Chicago
  • Chicago Medical Research, LLC - Hazel Crest - Hazel Crest

Indiana

  • Ascension Medical Group St. Vincent - Indianapolis Heart Care - Indianapolis
  • Local Institution - 0045 - Indianapolis

Missouri

  • St. Louis Heart and Vascular - St Louis
  • Local Institution - 0043 - St Louis

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • Colorado Heart and Vascular - Lakewood - Lakewood

Trial Details

FieldValue
Enrollment Target 208 participants
Start Date 2023-11-07
Est. Completion 2026-07-03
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06122779

The ClinicalTrials.gov registry entry for NCT06122779 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06122779 reports 20 study locations spanning 9 distinct geographic areas - top geographies include New York, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06122779 about?

NCT06122779 is a clinical study titled "Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)". The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).

What is the current status of trial NCT06122779?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2023-11-07. Estimated completion is 2026-07-03.

What conditions does trial NCT06122779 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT06122779?

The interventions under investigation include: Placebo (OTHER), BMS-986435 (DRUG).

Who is sponsoring clinical trial NCT06122779?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06122779 being conducted?

This trial has 20 study locations across Alabama, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.